NasdaqCM - Delayed Quote USD

Quoin Pharmaceuticals, Ltd. (QNRX)

4.5400 +0.4200 (+10.19%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026

GlobeNewswire 2d ago

QNRX
+10.19%
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

GlobeNewswire 11d ago

QNRX
+10.19%
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

GlobeNewswire 17d ago

QNRX
+10.19%
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

GlobeNewswire 25d ago

QNRX
+10.19%
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

GlobeNewswire 1mo ago

QNRX
+10.19%
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

GlobeNewswire 1mo ago

QNRX
+10.19%
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

GlobeNewswire 1mo ago

QNRX
+10.19%
Quoin in line for priority review voucher if rare paediatric drug approved

Pharmaceutical Technology 1mo ago

QNRX
+10.19%
JAZZ
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

GlobeNewswire 2mo ago

QNRX
+10.19%
QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

Zacks Small Cap Research 2mo ago

QNRX
+10.19%
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GlobeNewswire 2mo ago

QNRX
+10.19%
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

GlobeNewswire 3mo ago

QNRX
+10.19%

Performance Overview

Return	QNRX	MSCI WORLD (^990100-USD-STRD)
YTD	-66.37%	+9.75%
1-Year	-59.82%	+10.75%
3-Year	-96.81%	+73.81%

U.S. markets closed

Quoin Pharmaceuticals, Ltd. (QNRX)

Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin in line for priority review voucher if rare paediatric drug approved

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome